R&D expense · 2011–2025
Halozyme Therapeutics R&D expense
$81.5M+3.1% · FY2025
Halozyme Therapeutics (HALO) reported $81.5M in R&D expense for fiscal 2025, +3.1% year on year.
| Fiscal year | R&D expense | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $81.5M | +3.1% | Open → |
| FY20242024-12-31 | $79.0M | +3.5% | Open → |
| FY20232023-12-31 | $76.4M | +14.6% | Open → |
| FY20222022-12-31 | $66.6M | +86.7% | Open → |
| FY20212021-12-31 | $35.7M | +4.2% | Open → |
| FY20202020-12-31 | $34.2M | −75.7% | Open → |
| FY20192019-12-31 | $141M | −6.3% | Open → |
| FY20182018-12-31 | $150M | −0.3% | Open → |
| FY20172017-12-31 | $151M | −0.1% | Open → |
| FY20162016-12-31 | $151M | +61.8% | Open → |
| FY20152015-12-31 | $93.2M | +17.0% | Open → |
| FY20142014-12-31 | $79.7M | −17.5% | Open → |
| FY20132013-12-31 | $96.6M | +38.0% | Open → |
| FY20122012-12-31 | $70.0M | +21.7% | Open → |
| FY20112011-12-31 | $57.6M | — | Open → |
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2011–2025 compound annual growth +2.5%
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Halozyme Therapeutics R&D expense |url=https://companiesranked.com/en/company/halozyme-therapeutics/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Halozyme Therapeutics R&D expense. CompaniesRanked. https://companiesranked.com/en/company/halozyme-therapeutics/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-halozyme-therapeutics-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Halozyme Therapeutics R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/halozyme-therapeutics/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001159036-26-000024 · February 17, 2026
{{cite web |title=Halozyme Therapeutics R&D expense — 10-K (0001159036-26-000024) |url=https://www.sec.gov/Archives/edgar/data/1159036/000115903626000024/halo-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-17}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.